Brief: I-Mab Provides Business And Corporate Updates

NovaBridge Biosciences

29/03/2022 11:22

March 29 (Reuters) - I-Mab  IMAB.O :
    * I-MAB - TOTAL CASH POSITION OF US$671 MILLION WITH CASH
FLOW
FROM EXPECTED MILESTONE PAYMENTS OF PREVIOUS DEALS, SUFFICIENT
TO FUND BUSINESS OPERATIONS THROUGH 2025
    * I-MAB - ACCELERATING ITS EFFORT TO PURSUE A DUAL LISTING
TO
COMPLEMENT ITS NASDAQ INVESTOR BASE
    * I-MAB - TAKEN PROACTIVE MEASURES IN RESPONSE TO HOLDING
FOREIGN
COMPANIES ACCOUNTABLE ACT ANNOUNCEMENT
    * I-MAB - IMPLEMENTED ADDITIONAL BUSINESS PROCESSES AND
CONTROL
CHANGES TO MEET REQUIREMENTS SET FORTH IN OTHER APPLICABLE LAWS
AND REGULATIONS

Source text for Eikon:  ID:nPn9mlNDxa 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))